JP2024524933A5 - - Google Patents
Info
- Publication number
- JP2024524933A5 JP2024524933A5 JP2023577688A JP2023577688A JP2024524933A5 JP 2024524933 A5 JP2024524933 A5 JP 2024524933A5 JP 2023577688 A JP2023577688 A JP 2023577688A JP 2023577688 A JP2023577688 A JP 2023577688A JP 2024524933 A5 JP2024524933 A5 JP 2024524933A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- solvate
- isomer
- hydrate
- crystalline form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110661394.5 | 2021-06-15 | ||
| CN202110661394 | 2021-06-15 | ||
| PCT/CN2022/099018 WO2022262784A1 (zh) | 2021-06-15 | 2022-06-15 | Idh突变体抑制剂及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024524933A JP2024524933A (ja) | 2024-07-09 |
| JP2024524933A5 true JP2024524933A5 (OSRAM) | 2025-06-23 |
Family
ID=84526875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023577688A Pending JP2024524933A (ja) | 2021-06-15 | 2022-06-15 | Ｉｄｈ変異体阻害剤およびその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240208978A1 (OSRAM) |
| EP (1) | EP4356914A4 (OSRAM) |
| JP (1) | JP2024524933A (OSRAM) |
| KR (1) | KR20240021774A (OSRAM) |
| CN (1) | CN117460512A (OSRAM) |
| AU (1) | AU2022294860A1 (OSRAM) |
| BR (1) | BR112023024454A2 (OSRAM) |
| CA (1) | CA3217608A1 (OSRAM) |
| MX (1) | MX2023013664A (OSRAM) |
| WO (1) | WO2022262784A1 (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026035776A1 (en) * | 2024-08-05 | 2026-02-12 | Frontier Medicines Corporation | Pi3k-alpha binding compounds and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012184205A (ja) * | 2011-03-08 | 2012-09-27 | Dainippon Sumitomo Pharma Co Ltd | ２−アミノ置換８−オキソジヒドロプリン誘導体 |
| PT3415517T (pt) * | 2012-09-28 | 2022-05-13 | Takeda Pharmaceuticals Co | Forma cristalina de 1-(4-1-(2,6-difluorobenzil)-5- dimetilaminometil-3-(6-metoxipiridazin-3-il)-2,4-dioxo- 1,2,3,4-tetrahidrotieno(2,3-d)-pirimidin-6-il)fenil)-3- metoxiureia |
| KR20150131224A (ko) * | 2013-03-14 | 2015-11-24 | 노파르티스 아게 | 돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온 |
| MA46064B1 (fr) * | 2014-09-19 | 2020-04-30 | Forma Therapeutics Inc | Dérivés de pyridin-2-(1h)-one-quinolinone en tant qu'inhibiteurs d'isocitrate déshydrogénase |
| WO2016171755A1 (en) * | 2015-04-21 | 2016-10-27 | Forma Therapeutics, Inc. | Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
| JP6473270B2 (ja) * | 2015-07-27 | 2019-02-20 | イーライ リリー アンド カンパニー | ７−フェニルエチルアミノ−４ｈ−ピリミド［４，５−ｄ］［１，３］オキサジン−２−オン化合物及び変異体ｉｄｈ１阻害剤としてのそれらの使用 |
| ES2814290T3 (es) | 2016-06-06 | 2021-03-26 | Lilly Co Eli | Inhibidores de IDH1 mutante |
| CN107556366B (zh) * | 2016-06-30 | 2025-02-07 | 上海海和药物研究开发股份有限公司 | 具有突变型异柠檬酸脱氢酶抑制活性的化合物、其制备方法及用途 |
| EP3489230B1 (en) * | 2016-07-21 | 2021-12-08 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Chemical compound of isocitrate dehydrogenase inhibitor, and application thereof |
| PH12019501328B1 (en) | 2016-12-16 | 2023-05-12 | Lilly Co Eli | 7-phenylethlamino-4h-pyrimido][4,5-d][1,3] oxazin-2-one compounds as mutant 1dh1 and 1dh2 inhibitors |
| WO2020048347A1 (zh) * | 2018-09-04 | 2020-03-12 | 上海再极医药科技有限公司 | 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用 |
| US20200206233A1 (en) * | 2018-12-31 | 2020-07-02 | Integral Biosciences Private Limited | Heterocyclic compounds as mutant idh inhibitors |
-
2022
- 2022-06-15 US US18/287,885 patent/US20240208978A1/en active Pending
- 2022-06-15 CA CA3217608A patent/CA3217608A1/en active Pending
- 2022-06-15 WO PCT/CN2022/099018 patent/WO2022262784A1/zh not_active Ceased
- 2022-06-15 EP EP22824259.0A patent/EP4356914A4/en active Pending
- 2022-06-15 KR KR1020237041032A patent/KR20240021774A/ko active Pending
- 2022-06-15 JP JP2023577688A patent/JP2024524933A/ja active Pending
- 2022-06-15 BR BR112023024454A patent/BR112023024454A2/pt unknown
- 2022-06-15 CN CN202280040684.0A patent/CN117460512A/zh active Pending
- 2022-06-15 MX MX2023013664A patent/MX2023013664A/es unknown
- 2022-06-15 AU AU2022294860A patent/AU2022294860A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024516371A5 (OSRAM) | ||
| JP2021063088A5 (OSRAM) | ||
| JP2024071370A5 (OSRAM) | ||
| JP2021191784A5 (OSRAM) | ||
| JP2023512175A5 (OSRAM) | ||
| JP2025013344A5 (OSRAM) | ||
| ES2295009T3 (es) | Inhibidores de rho quinasa para la profilaxis y el tratamiento de neumonia intersticial y fibrosis pulmonar. | |
| JP2022191257A5 (OSRAM) | ||
| JP2022502500A5 (OSRAM) | ||
| JP2017528503A5 (OSRAM) | ||
| JP2017528507A5 (OSRAM) | ||
| JP2025161856A5 (OSRAM) | ||
| JP2017531619A5 (OSRAM) | ||
| TW201247613A (en) | Ester derivatives of bimatoprost compositions and methods | |
| JP2021521118A5 (OSRAM) | ||
| JP2021167346A5 (OSRAM) | ||
| JP2021520400A (ja) | エダラボン医薬組成物 | |
| JP2013500977A5 (OSRAM) | ||
| JP2022538817A5 (OSRAM) | ||
| JP2019536812A5 (OSRAM) | ||
| JP2024541569A5 (OSRAM) | ||
| JP2016516773A5 (OSRAM) | ||
| JP2022531251A5 (OSRAM) | ||
| JP2024516359A5 (OSRAM) | ||
| JP2009517411A5 (OSRAM) |